Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00789373 · OUTCOME

Percentage of Participants With Serious Adverse Events During Maintenance Phase

A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer · Source last updated 2018-12-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)

What was measured

A summary of serious adverse events is located in the Reported Adverse Event Module.

Analysis population: Randomized population with all serious adverse events included.

Groups in this outcome

Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed

pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care

Pemetrexed Plus Cisplatin Followed by Placebo

pemetrexed + cisplatin followed by placebo plus best supportive care

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed359
Pemetrexed Plus Cisplatin Followed by Placebo180

Reported measurements

Serious Adverse Events: up to 19.3 Months
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed18.9Not reportedNot reportedNot reportedNot reported
Pemetrexed Plus Cisplatin Followed by Placebo12.2Not reportedNot reportedNot reportedNot reported
Serious Adverse Events: up to 49.7 Months
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed26.2Not reportedNot reportedNot reportedNot reported
Pemetrexed Plus Cisplatin Followed by Placebo20.0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        18.9
      2. group Id
        OG001
        value
        12.2
    title
    Serious Adverse Events: up to 19.3 Months
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        26.2
      2. group Id
        OG001
        value
        20.0
    title
    Serious Adverse Events: up to 49.7 Months
denoms
  1. counts
    1. group Id
      OG000
      value
      359
    2. group Id
      OG001
      value
      180
    units
    Participants
description
A summary of serious adverse events is located in the Reported Adverse Event Module.
groups
  1. description
    pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care
    id
    OG000
    title
    Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed
  2. description
    pemetrexed + cisplatin followed by placebo plus best supportive care
    id
    OG001
    title
    Pemetrexed Plus Cisplatin Followed by Placebo
param Type
NUMBER
population Description
Randomized population with all serious adverse events included.
reporting Status
POSTED
time Frame
Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)
title
Percentage of Participants With Serious Adverse Events During Maintenance Phase
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice